The Erythromelalgia drugs in development market research report provides comprehensive information on the therapeutics under development for Erythromelalgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Erythromelalgia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Erythromelalgia and features dormant and discontinued products.
GlobalData tracks six drugs in development for Erythromelalgia by six companies/universities/institutes. The top development phase for Erythromelalgia is preclinical with four drugs in that stage. The Erythromelalgia pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Erythromelalgia pipeline products market are: Chromocell Therapeutics, Brighton Biotech and Pila Pharma.
The key targets in the Erythromelalgia pipeline products market include Sodium Channel Protein Type 9 Subunit Alpha, Sodium Channel Protein Type 11 Subunit Alpha, and Sodium Channel Protein Type 10 Subunit Alpha.
The key mechanisms of action in the Erythromelalgia pipeline product include Sodium Channel Protein Type 9 Subunit Alpha Blocker with two drugs in Phase II. The Erythromelalgia pipeline products include six routes of administration with the top ROA being Oral and two key molecule types in the Erythromelalgia pipeline products market including Small Molecule, and Gene Therapy.
Erythromelalgia overview
Erythromelalgia is a rare clinical syndrome characterized by a triad of redness, warmth, and burning pain, most notably affecting the extremities. It usually affects the lower extremities (most commonly feet) or may involve upper extremities (hands) in few cases.
For a complete picture of Erythromelalgia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
